ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?

被引：1
|
作者：
Kumar, Naveen [1 ]
机构：
[1] Medanta Hosp, Dept Urol, Patna, Bihar, India
来源：
INDIAN JOURNAL OF UROLOGY | 2022年 / 38卷 / 03期
关键词：
D O I：
10.4103/iju.iju_81_22
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：238 / 239
页数：2
相关论文
共 50 条
  • [1] COMBINATION OF DAROLUTAMIDE WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL INCREASES SURVIVAL FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN THE PHASE 3 ARASENS STUDY
    Olivier, Kara
    Tombal, Betrand
    Thiele, Silke
    Li, Rui
    Joensuu, Heikki
    Smith, Matthew
    ONCOLOGY NURSING FORUM, 2022, 49 (02) : 20 - 20
  • [2] Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
    Hussain, Maha
    Tombal, Bertrand
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Shore, Neal
    Kopyltsov, Evgeny
    Kalebasty, Arash Rezazadeh
    Boegemann, Martin
    Ye, Dingwei
    Cruz, Felipe
    Suzuki, Hiroyoshi
    Kapur, Shivani
    Srinivasan, Shankar
    Verholen, Frank
    Kuss, Iris
    Joensuu, Heikki
    Smith, Matthew R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (20) : 3595 - +
  • [3] Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial
    Todenhoefer, Tilman
    Smith, Matthew R.
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, David
    Kopyltsov, Evgeny
    Park, Chandler H.
    Alekseev, Boris
    Pino, Alvaro Montesa
    Ye, Dingwei
    Parnis, Francis
    Tammela, Teuvo
    Suzuki, Hiroyoshi
    Joensuu, Heikki
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Tombal, Bertrand
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 110 - 110
  • [4] Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk in the Phase 3 ARASENS Study
    Hovey, Elizabeth
    Hussain, Maha
    Tombal, Bertrand
    Saad, Fred
    Fizazi, Karim
    Sternberg, Coran
    Crawford, E. David
    Shore, Neal
    Kopyltsov, Evgeny
    Rezazadeh Kalebasty, Arash
    Bogemann, Martin
    Ye Dingwei
    Cruz, Felipe
    Suzuki, Hiroyoshi
    Verholen, Frank
    Srinivasan, Shankar
    Kuss, Iris
    Joensuu, Heikki
    Smith, Matthew R.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 64 - 64
  • [5] Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.
    Smith, Matthew Raymond
    Hussain, Maha H. A.
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kopyltsov, Evgeny
    Park, Chandler H.
    Alexeev, Boris
    Montesa, Alvaro
    Ye, Dingwei
    Parnis, Francis
    Cruz, Felipe Melo
    Tammela, Teuvo
    Suzuki, Hiroyoshi
    Joensuu, Heikki
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [6] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study
    Kalebasty, Arash Rezazadeh
    Hammerer, Peter
    Tombal, Bertrand
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, David
    Zhang, Weijiang
    Ploeger, Bart
    Li, Rui
    Kuss, Iris
    Zieschang, Carsten
    Wittemer-Rump, Sabine
    Smith, Mathew
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 80 - 81
  • [7] Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
    Saad, Fred
    Vjaters, Egils
    Shore, Neal
    Olmos, David
    Xing, Nianzeng
    Pereira de Santana Gomes, Andrea Juliana
    Cesar de Andrade Mota, Augusto
    Salman, Pamela
    Jievaltas, Mindaugas
    Ulys, Albertas
    Jakubovskis, Maris
    Kopyltsov, Evgeny
    Han, Weiqing
    Nevalaita, Liina
    Testa, Isabella
    Le Berre, Marie-Aude
    Kuss, Iris
    Haresh, Kunhi Parambath
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (36)
  • [8] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study.
    Rezazadeh, Arash
    Tombal, Bertrand F.
    Hussain, Maha H. A.
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kapur, Shivani
    Zhang, Weijiang
    Ploeger, Bart
    Li, Rui
    Kuss, Iris
    Zieschang, Carsten
    Wittemer-Rump, Sabine
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [9] Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?
    Hoeh, Benedikt
    Chun, Felix K. H.
    Mandel, Philipp
    CHINESE CLINICAL ONCOLOGY, 2024, 13 (01)
  • [10] Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS
    Tombal, B.
    Smith, M. R.
    Hussain, M.
    Saad, F.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Kapur, S.
    Zhang, W.
    Ploeger, B.
    Li, R.
    Kuss, I.
    Zieschang, C.
    Wittemer-Rump, S.
    Rezazadeh, Kalebasty A.
    EUROPEAN UROLOGY, 2023, 83
12345